Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Brain ; 146(12): 5235-5248, 2023 12 01.
Article in English | MEDLINE | ID: mdl-37503746

ABSTRACT

The extracellular matrix (ECM) has an important role in the development and maintenance of skeletal muscle, and several muscle diseases are associated with the dysfunction of ECM elements. MAMDC2 is a putative ECM protein and its role in cell proliferation has been investigated in certain cancer types. However, its participation in skeletal muscle physiology has not been previously studied. We describe 17 individuals with an autosomal dominant muscular dystrophy belonging to two unrelated families in which different heterozygous truncating variants in the last exon of MAMDC2 co-segregate correctly with the disease. The radiological aspect of muscle involvement resembles that of COL6 myopathies with fat replacement at the peripheral rim of vastii muscles. In this cohort, a subfascial and peri-tendinous pattern is observed in upper and lower limb muscles. Here we show that MAMDC2 is expressed in adult skeletal muscle and differentiating muscle cells, where it appears to localize to the sarcoplasm and myonuclei. In addition, we show it is secreted by myoblasts and differentiating myotubes into to the extracellular compartment. The last exon encodes a disordered region with a polar residue compositional bias loss of which likely induces a toxic effect of the mutant protein. The precise mechanisms by which the altered MAMDC2 proteins cause disease remains to be determined. MAMDC2 is a skeletal muscle disease-associated protein. Its role in muscle development and ECM-muscle communication remains to be fully elucidated. Screening of the last exon of MAMDC2 should be considered in patients presenting with autosomal dominant muscular dystrophy, particularly in those with a subfascial radiological pattern of muscle involvement.


Subject(s)
Muscular Dystrophies , Adult , Humans , Muscular Dystrophies/genetics , Muscle, Skeletal/metabolism , Extracellular Matrix Proteins
2.
Front Cell Dev Biol ; 11: 1128534, 2023.
Article in English | MEDLINE | ID: mdl-37228645

ABSTRACT

Aged muscles accumulate satellite cells with a striking decline response to damage. Although intrinsic defects in satellite cells themselves are the major contributors to aging-associated stem cell dysfunction, increasing evidence suggests that changes in the muscle-stem cell local microenvironment also contribute to aging. Here, we demonstrate that loss of the matrix metalloproteinase-10 (MMP-10) in young mice alters the composition of the muscle extracellular matrix (ECM), and specifically disrupts the extracellular matrix of the satellite cell niche. This situation causes premature features of aging in the satellite cells, contributing to their functional decline and a predisposition to enter senescence under proliferative pressure. Similarly, reduction of MMP-10 levels in young satellite cells from wild type animals induces a senescence response, while addition of the protease delays this program. Significantly, the effect of MMP-10 on satellite cell aging can be extended to another context of muscle wasting, muscular dystrophy. Systemic treatment of mdx dystrophic mice with MMP-10 prevents the muscle deterioration phenotype and reduces cellular damage in the satellite cells, which are normally under replicative pressure. Most importantly, MMP-10 conserves its protective effect in the satellite cell-derived myoblasts isolated from a Duchenne muscular dystrophy patient by decreasing the accumulation of damaged DNA. Hence, MMP-10 provides a previously unrecognized therapeutic opportunity to delay satellite cell aging and overcome satellite cell dysfunction in dystrophic muscles.

3.
JCI Insight ; 4(17)2019 09 05.
Article in English | MEDLINE | ID: mdl-31484827

ABSTRACT

Deficiency of arginase is associated with hyperargininemia, and prominent features include spastic diplegia/tetraplegia, clonus, and hyperreflexia; loss of ambulation, intellectual disability and progressive neurological decline are other signs. To gain greater insight into the unique neuromotor features, we performed gene expression profiling of the motor cortex of a murine model of the disorder. Coexpression network analysis suggested an abnormality with myelination, which was supported by limited existing human data. Utilizing electron microscopy, marked dysmyelination was detected in 2-week-old homozygous Arg1-KO mice. The corticospinal tract was found to be adversely affected, supporting dysmyelination as the cause of the unique neuromotor features and implicating oligodendrocyte impairment in a deficiency of hepatic Arg1. Following neonatal hepatic gene therapy to express Arg1, the subcortical white matter, pyramidal tract, and corticospinal tract all showed a remarkable recovery in terms of myelinated axon density and ultrastructural integrity with active wrapping of axons by nearby oligodendrocyte processes. These findings support the following conclusions: arginase deficiency is a leukodystrophy affecting the brain and spinal cord while sparing the peripheral nervous system, and neonatal AAV hepatic gene therapy can rescue the defects associated with myelinated axons, strongly implicating the functional recovery of oligodendrocytes after restoration of hepatic arginase activity.


Subject(s)
Arginase/genetics , Genetic Predisposition to Disease/genetics , Hyperargininemia/genetics , Hyperargininemia/metabolism , Liver/enzymology , Liver/metabolism , Animals , Arginase/metabolism , Axons/metabolism , Axons/pathology , Central Nervous System/diagnostic imaging , Central Nervous System/pathology , Disease Models, Animal , Female , Gene Expression Profiling , Gene Expression Regulation , Genetic Therapy , Homozygote , Hyperargininemia/pathology , Male , Mice , Mice, Knockout , Oligodendroglia/metabolism , Transcriptome
4.
J Neurosci ; 36(25): 6680-90, 2016 06 22.
Article in English | MEDLINE | ID: mdl-27335400

ABSTRACT

UNLABELLED: Arginase 1 deficiency is a urea cycle disorder associated with hyperargininemia, spastic diplegia, loss of ambulation, intellectual disability, and seizures. To gain insight on how loss of arginase expression affects the excitability and synaptic connectivity of the cortical neurons in the developing brain, we used anatomical, ultrastructural, and electrophysiological techniques to determine how single-copy and double-copy arginase deletion affects cortical circuits in mice. We find that the loss of arginase 1 expression results in decreased dendritic complexity, decreased excitatory and inhibitory synapse numbers, decreased intrinsic excitability, and altered synaptic transmission in layer 5 motor cortical neurons. Hepatic arginase 1 gene therapy using adeno-associated virus rescued nearly all these abnormalities when administered to neonatal homozygous knock-out animals. Therefore, gene therapeutic strategies can reverse physiological and anatomical markers of arginase 1 deficiency and therefore may be of therapeutic benefit for the neurological disabilities in this syndrome. SIGNIFICANCE STATEMENT: These studies are one of the few investigations to try to understand the underlying neurological dysfunction that occurs in urea cycle disorders and the only to examine arginase deficiency. We have demonstrated by multiple modalities that, in murine layer 5 cortical neurons, a gradation of abnormalities exists based on the functional copy number of arginase: intrinsic excitability is altered, there is decreased density in asymmetrical and perisomatic synapses, and analysis of the dendritic complexity is lowest in the homozygous knock-out. With neonatal administration of adeno-associated virus expressing arginase, there is near-total recovery of the abnormalities in neurons and cortical circuits, supporting the concept that neonatal gene therapy may prevent the functional abnormalities that occur in arginase deficiency.


Subject(s)
Arginase/therapeutic use , Genetic Therapy , Hyperargininemia/pathology , Hyperargininemia/therapy , Motor Cortex/physiology , Recovery of Function/physiology , Action Potentials/drug effects , Action Potentials/physiology , Ammonia/blood , Animals , Animals, Newborn , Arginase/genetics , Arginase/metabolism , Disease Models, Animal , Hyperargininemia/blood , In Vitro Techniques , Mice , Mice, Transgenic , Motor Cortex/cytology , Motor Cortex/ultrastructure , Nerve Net/pathology , Nerve Net/physiology , Nerve Net/ultrastructure , Neurons/physiology , Neurons/ultrastructure , Picrotoxin/pharmacology , Sodium Channel Blockers/pharmacology , Synapses/ultrastructure , Tetrodotoxin/pharmacology
5.
Proc Natl Acad Sci U S A ; 110(41): 16562-7, 2013 Oct 08.
Article in English | MEDLINE | ID: mdl-24023061

ABSTRACT

Deposition of insoluble protein aggregates is a hallmark of neurodegenerative diseases. The universal presence of ß-amyloid and tau in Alzheimer's disease (AD) has facilitated advancement of the amyloid cascade and tau hypotheses that have dominated AD pathogenesis research and therapeutic development. However, the underlying etiology of the disease remains to be fully elucidated. Here we report a comprehensive study of the human brain-insoluble proteome in AD by mass spectrometry. We identify 4,216 proteins, among which 36 proteins accumulate in the disease, including U1-70K and other U1 small nuclear ribonucleoprotein (U1 snRNP) spliceosome components. Similar accumulations in mild cognitive impairment cases indicate that spliceosome changes occur in early stages of AD. Multiple U1 snRNP subunits form cytoplasmic tangle-like structures in AD but not in other examined neurodegenerative disorders, including Parkinson disease and frontotemporal lobar degeneration. Comparison of RNA from AD and control brains reveals dysregulated RNA processing with accumulation of unspliced RNA species in AD, including myc box-dependent-interacting protein 1, clusterin, and presenilin-1. U1-70K knockdown or antisense oligonucleotide inhibition of U1 snRNP increases the protein level of amyloid precursor protein. Thus, our results demonstrate unique U1 snRNP pathology and implicate abnormal RNA splicing in AD pathogenesis.


Subject(s)
Alternative Splicing/physiology , Alzheimer Disease/physiopathology , Brain/metabolism , Proteome/metabolism , Ribonucleoprotein, U1 Small Nuclear/metabolism , Spliceosomes/metabolism , Alternative Splicing/genetics , Blotting, Western , Chromatography, Liquid , Fluorescent Antibody Technique , High-Throughput Nucleotide Sequencing , Humans , Immunohistochemistry , Proteome/genetics , Proteomics , Reverse Transcriptase Polymerase Chain Reaction , Tandem Mass Spectrometry
6.
J Neurosci ; 30(21): 7377-91, 2010 May 26.
Article in English | MEDLINE | ID: mdl-20505105

ABSTRACT

The continuous release of neurotransmitter could be seen to place a persistent burden on presynaptic proteins, one that could compromise nerve terminal function. This supposition and the molecular mechanisms that might protect highly active synapses merit investigation. In hippocampal cultures from knock-out mice lacking the presynaptic cochaperone cysteine string protein-alpha (CSP-alpha), we observe progressive degeneration of highly active synaptotagmin 2 (Syt2)-expressing GABAergic synapses, but surprisingly not of glutamatergic terminals. In CSP-alpha knock-out mice, synaptic degeneration of basket cell terminals occurs in vivo in the presence of normal glutamatergic synapses onto dentate gyrus granule cells. Consistent with this, in hippocampal cultures from these mice, the frequency of miniature IPSCs, caused by spontaneous GABA release, progressively declines, whereas the frequency of miniature excitatory AMPA receptor-mediated currents (mEPSCs), caused by spontaneous release of glutamate, is normal. However, the mEPSC amplitude progressively decreases. Remarkably, long-term block of glutamatergic transmission in cultures lacking CSP-alpha substantially rescues Syt2-expressing GABAergic synapses from neurodegeneration. These findings demonstrate that elevated neural activity increases synapse vulnerability and that CSP-alpha is essential to maintain presynaptic function under a physiologically high-activity regimen.


Subject(s)
Inhibitory Postsynaptic Potentials/physiology , Nerve Degeneration/metabolism , Synapses/metabolism , gamma-Aminobutyric Acid/metabolism , Age Factors , Animals , Animals, Newborn , Astrocytes/physiology , Bicuculline/pharmacology , Cells, Cultured , Excitatory Amino Acid Agents/pharmacology , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/genetics , GABA Agents/pharmacology , Gene Expression Regulation, Developmental/genetics , Gene Expression Regulation, Developmental/physiology , Glutamic Acid/metabolism , HSP40 Heat-Shock Proteins/deficiency , Hippocampus/cytology , Inhibitory Postsynaptic Potentials/drug effects , Inhibitory Postsynaptic Potentials/genetics , Membrane Proteins/deficiency , Mice , Mice, Knockout , Microscopy, Confocal/methods , Microscopy, Electron, Transmission/methods , Mutation/genetics , Nerve Degeneration/genetics , Nerve Tissue Proteins/metabolism , Neurons/cytology , Patch-Clamp Techniques , Presynaptic Terminals/metabolism , Presynaptic Terminals/ultrastructure , Rats , Synapses/genetics , Synapses/ultrastructure
7.
Mutat Res ; 644(1-2): 24-30, 2008 Sep 26.
Article in English | MEDLINE | ID: mdl-18640132

ABSTRACT

It has been recently proposed that hypomethylation of DNA induced by 5-azacytidine (5-azaC) leads to reduced chromatid decatenation that ends up in endoreduplication, most likely due to a failure in topo II function [S. Mateos, I. Domínguez, N. Pastor, G. Cantero, F. Cortés, The DNA demethylating 5-azaC induces endoreduplication in cultured Chinese hamster cells, Mutat. Res. 578 (2005) 33-42]. The Chinese hamster mutant cell line EM9 has a high spontaneous frequency of endoreduplication as compared to its parental line AA8. In order to see if this is related to the degree of DNA methylation, we have investigated the basal levels of both endpoints in AA8 and EM9, as well as the effect of extensive 5-azaC-induced demethylation on the production of endoreduplication. Based on the correlation between the levels of DNA methylation and indices of endoreduplication we propose that genomic DNA hypomethylation in EM9 cell line is probably an important factor that bears significance in relation to the high basal level of endoreduplication observed in this cell line.


Subject(s)
DNA Methylation , DNA Repair/genetics , Deoxycytidine/metabolism , Mutation , Animals , Azacitidine/pharmacology , CHO Cells , Chromosomes/genetics , Chromosomes/metabolism , Chromosomes/ultrastructure , Cricetinae , Cricetulus , DNA Replication/drug effects , Deoxycytidine/analogs & derivatives
8.
Mutat Res ; 637(1-2): 40-8, 2008 Jan 01.
Article in English | MEDLINE | ID: mdl-17706727

ABSTRACT

The fundamental nuclear enzyme DNA topoisomerase I (topo I), cleaves the double-stranded DNA molecule at preferred sequences within its recognition/binding sites. We have recently reported that when cells incorporate halogenated nucleosides analogues of thymidine into DNA, it interferes with normal chromosome segregation, as shown by an extraordinarily high yield of endoreduplication, and results in a protection against DNA breakage induced by the topo II poison m-AMSA [F. Cortés, N. Pastor, S. Mateos, I. Domínguez, The nature of DNA plays a role in chromosome segregation: endoreduplication in halogen-substituted chromosomes, DNA Repair 2 (2003) 719-726; G. Cantero, S. Mateos, N. Pastor; F. Cortés, Halogen substitution of DNA protects from poisoning of topoisomerase II that results in DNA double-strand breaks (DSBs), DNA Repair 5 (2006) 667-674]. In the present investigation, we have assessed whether the presence of halogenated nucleosides in DNA diminishes the frequency of interaction of topo I with DNA and thus the frequency with which the stabilisation of cleavage complexes by the topo I poison camptothecin (CPT) takes place, in such a way that it protects from chromosome breakage and sister-chromatid exchange. This protective effect is shown to parallel a loss in halogen-substituted cells of the otherwise CPT-increased catalytic activity bound to DNA.


Subject(s)
Camptothecin/pharmacology , DNA/metabolism , Halogens/metabolism , Sister Chromatid Exchange , Topoisomerase I Inhibitors , Animals , CHO Cells , Cricetinae , Cricetulus , DNA Damage/drug effects , Enzyme Inhibitors/pharmacology
9.
Mutat Res ; 599(1-2): 160-6, 2006 Jul 25.
Article in English | MEDLINE | ID: mdl-16574165

ABSTRACT

It has been proposed that polyploid cells that arise during a variety of pathological conditions and as a result of exposure to genotoxicants, typically in the liver, become aneuploid through genetic instability. Aneuploidy contributes to, or even drives, tumour development. We have assessed the capacity of the drug cisplatin, one of the most commonly used compounds for the treatment of malignancies, to induce endoreduplication, a particular type of polyploidy, in cultured Chinese hamster AA8 cells. Taking into account that any interference with DNA topoisomerase II (topo II) function leads to endoreduplication, we have found that treatment of the cells with this platinum compound results in a dose-dependent inhibition of the catalytic activity of the enzyme. These observations are discussed on the basis of a possible dual action of cisplatin leading to a combined negative effect on normal segregation of chromosomes. On the one hand, through the drug capacity to efficiently inhibiting the catalytic activity of topo II itself and, on the other hand, as a consequence of changes in DNA such as base modifications and cross-links that result from cisplatin treatment, likely leading to a lack of recognition/binding of DNA by the enzyme. These observations support a model in which the involvement of topo II in different pathways leading to induced endoreduplication has been proposed, and seem to bear significance as to the possible origin of the development of secondary tumours as a result of cisplatin treatment of primary malignancies.


Subject(s)
Aneugens/toxicity , Antineoplastic Agents/toxicity , Cisplatin/toxicity , DNA Damage , Polyploidy , Topoisomerase II Inhibitors , Aneuploidy , Animals , CHO Cells , Cricetinae , Enzyme Inhibitors/toxicity , Humans , Neoplasms, Second Primary/chemically induced , Neoplasms, Second Primary/genetics
10.
DNA Repair (Amst) ; 5(6): 667-74, 2006 Jun 10.
Article in English | MEDLINE | ID: mdl-16406738

ABSTRACT

DNA topoisomerase II (topo II), a fundamental nuclear enzyme, cleaves the double-stranded DNA molecule at preferred sequences within its recognition/binding sites. We have recently reported [F. Cortés, N. Pastor, S. Mateos, I. Domínguez, The nature of DNA plays a role in chromosome segregation: endoreduplication in halogen-substituted chromosomes, DNA Repair 2 (2003) 719-726] that when cells incorporate halogenated nucleosides analogues of thymidine into DNA, it interferes with normal chromosome segregation, as shown by an extraordinarily high yield of endoreduplication. The frequency of endoreduplicated cells paralleled the level of analogue substitution into DNA, lending support to the idea that thymidine analogue substitution into DNA is most likely responsible for the triggering of endoreduplication. Using the pulsed-field gel electrophoresis (PFGE) technique, we have now analyzed a possible protection provided by the incorporation of exogenous halogenated nucleosides against DNA breakage induced by the topo II poison m-AMSA. The result was that the different halogenated nucleosides were shown as able to protect DNA from double-strand breaks induced by m-AMSA depending such a protection upon the relative percent of incorporation of a given thymidine analogue into DNA. Our results clearly indicate that the presence of halogenated nucleosides in DNA diminishes the frequency of interaction of topo II with DNA and thus the frequency with which cleavage can occur.


Subject(s)
DNA Damage , DNA Topoisomerases, Type II/chemistry , DNA/chemistry , Halogens/chemistry , Animals , CHO Cells , Cell Cycle , Cell Nucleus/metabolism , Chromosomes/ultrastructure , Cricetinae , DNA Topoisomerases, Type II/metabolism , Electrophoresis, Gel, Pulsed-Field , Models, Genetic , Nucleosides/chemistry , Saccharomyces cerevisiae/metabolism
11.
Mutat Res ; 578(1-2): 33-42, 2005 Oct 15.
Article in English | MEDLINE | ID: mdl-16202795

ABSTRACT

We have investigated the possible influence of 5-azacytidine (5-azaC) substitution for cytidine into DNA on topoisomerase II (topo II) function in chromosome segregation. The endpoint chosen has been the induction of endoreduplicated cells at mitosis showing diplochromosomes. Experiments were performed in the presence and absence of the cytidine analogue to assess the degree of 5-azaC-induced DNA hypomethylation, using differential cutting by restriction endonucleases Hpa II and Msp I. Using the pulsed-field gel electrophoresis (PFGE) technique, we have also observed a protective effect provided by 5-azaC treatment against DNA breakage induced by the topo II poison m-AMSA. Concentrations of 5-azaC shown as able to induce extensive DNA hypomethylation and capable to protect DNA from double-strand breaks induced by m-AMSA were used for our cytogenetic experiments to analyze chromosome segregation. Our results seem to indicate that the presence of 5-azaC in DNA induces a dose-dependent increase in the yield of endoreduplicated cells that parallels the levels of hypomethylation observed.


Subject(s)
Antineoplastic Agents/pharmacology , Azacitidine/pharmacology , DNA Replication/drug effects , DNA/metabolism , Methylation/drug effects , Amsacrine/pharmacology , Animals , CHO Cells , Chromosome Segregation , Chromosomes , Cricetinae , Cricetulus , DNA Damage/drug effects , DNA Restriction Enzymes/pharmacology , Dose-Response Relationship, Drug , Electrophoresis, Gel, Pulsed-Field , Topoisomerase II Inhibitors
12.
Mutat Res ; 582(1-2): 11-9, 2005 Apr 04.
Article in English | MEDLINE | ID: mdl-15781205

ABSTRACT

With the ultimate purpose of testing the hypothesis that, as shown in yeast mutants, any malfunction of DNA topoisomerase II might result in aberrant mitosis due to defective chromosome segregation, we have chosen three chemicals of different nature, recently reported to catalytically inhibit the enzyme. The endpoint selected to assess any negative effect on the ability of topoisomerase II to properly carry out decatenation of fully replicated chromosomes in the G2/M phase of the cell cycle was the presence of metaphases showing diplochromosomes as a result of endoreduplication, i.e. two successive rounds of DNA replication without intervening mitosis. The anti-topoisomerase drugs selected were the anthracycline antibiotic and antineoplastic agent aclarubicin, the respiratory venom sodium azide, and 9-aminoacridine, a chemical compound with planar topology capable of intercalation between DNA bases. Our results show that the three chemicals tested are able to induce endoreduplication to different degrees. These observations seem to lend support to the proposal that topoisomerase II plays a central role in chromosome segregation in mammalian cells.


Subject(s)
Chromosomes , Enzyme Inhibitors/pharmacology , Topoisomerase II Inhibitors , Animals , Catalysis , Cell Cycle/genetics , Cell Line , Cricetinae , Cricetulus , DNA Topoisomerases, Type II/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...